Academic Editor

Article Metrics

  • Fig. 1.

    View in Article
    Full Image
  • Fig. 2.

    View in Article
    Full Image
  • Fig. 3.

    View in Article
    Full Image
  • Fig. 4.

    View in Article
    Full Image
  • Fig. 5.

    View in Article
    Full Image
  • Information

  • Download

  • Contents

Abstract

Background:

Acute lung injury (ALI) significantly impacts the survival rates in intensive care units (ICU). Releasing a lot of pro-inflammatory mediators during the progression of the disease is a core feature of ALI, which may lead to uncontrolled inflammation and further damages the tissues and organs of patients. This study explores the potential therapeutic mechanisms of Dexmedetomidine (Dex) in ALI.

Methods:

In present study, cecal ligation puncture (CLP)-established ALI model mice and lipopolysaccharide (LPS)-stimulated RAW264.7 cell line were established to discover the influence of Dex. The evaluation of lung injury in vivo using histopathology, TUNEL assay, and analysis of inflammatory factors in bronchoalveolar lavage fluid (BALF) and serum. The receptor for advanced glycation end products (RAGE)/Caspase-11-dependent pyroptosis-related proteins and macrophage polarization markers were analyzed using western blot, immunofluorescence, and flow cytometry. Finally, the mechanism of Dex in macrophages was further verified in vitro.

Results:

In vivo, Dex alleviated lung injury and decreased TUNEL-positive cell expression in CLP group. Dex decreased tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6 and IL-17A levels in BALF and serum, while increasing IL-10 expression. Dex treatment decreased the protein levels of RAGE, caspase-11, IL-1β and Gasdermin-D (GSDMD) in both in cells and in mice. Dex also down-regulated the synthesis of inducible nitric oxide synthase (iNOS) of classical activation phenotype (M1) markers, and up-regulated the synthesis of CD206 and Arg-1 of alternate activation phenotype (M2) markers.

Conclusions:

Dex treatment can inhibit inflammation and reduce lung injury caused by CLP. It could be associated with mediating M1 and M2 polarization and suppressing RAGE/Caspase-11-depended pyroptosis.

1. Introduction

Acute lung injury (ALI) and the syndrome after progression, acute respiratory distress syndrome (ARDS), are progressive diseases characterized by hypoxemia unresponsive to oxygen therapy, bilateral pulmonary infiltration, and increased lung consolidations [1]. The immune mechanisms underlying ALI remain incompletely understood. One of the suggested mechanisms by which ALI develops is an excessive and uncontrolled inflammatory state [2], which is closely linked to high morbidity and mortality [3, 4]. Despite increasing knowledge of ALI/ARDS pathogenesis, there are still no effective treatment strategies. Hence, finding alternative treatments for ALI/ARDS is an urgent medical need. Recent study has indicated that although the disease is highly heterogeneous and clinically complex, it may be possible to find personalized pharmacologic therapies to inhibit inflammation and improve this disorder [5].

Dexmedetomidine (Dex) is a short-acting, highly selective α-2 adrenoreceptor agonist commonly used in clinical anesthesia and intensive care for its sedative, anxiolytic, analgesic, and sympatholytic properties [6]. At present, reports have indicated that Dex has organ-protecting and anti-inflammatory effects [7]. Recent evidence indicates that Dex may mitigate sepsis-induced acute liver damage by inhibiting TLR-4-mediated inflammatory cytokine release [8]. Research has shown that Dex reduces cell apoptosis and promotes cell survival in lung-related studies [9]. However, it is completely unknown whether, and by which mechanisms, Dex can play a role in treating ALI/ARDS.

In the initial progression of ALI, several pro-inflammatory cytokines and mediators are released, which may lead to uncontrolled inflammation and further damage to the tissues and organs of patients [10]. Dysfunction of immune regulation secondary to excessive inflammation is a key event in exacerbating ALI [11]. Therefore, inhibiting early uncontrolled inflammation, and improving immune regulation, may offer a new treatment method for ALI [12]. Macrophages are essential in regulating inflammation within the innate immune system. There are two types of polarization processes they undergo depending on how they respond to the internal environmental challenge, classical activation phenotype (M1) and alternate activation phenotype (M2) [13]. Increasingly, articles have reviewed the role of these two subtypes of macrophage in immune responses, and it seems possible that their appearance can influence the fate and development of diseases [14, 15]. M1 has been shown to exacerbate lung damage, whereas M2 promotes lung repair [16]. Macrophage subtypes and polarization are closely linked to ALI prognosis.

Pyroptosis, a type of programmed necrosis in the innate immune response, disrupts pathogen replication sites and kills intracellular bacteria via pore-induced intracellular traps [17, 18]. While beneficial, pyroptosis can cause uncontrolled inflammation if over-activated. Previous studies have shown that pyroptosis exacerbates the development of ALI [19, 20].

In terms of whether Dex protects against ALI/ARDS, and the possible underlying molecular mechanisms by which this could occur, have not yet been investigated. This study aims to the protective potential and mechanism of Dex in ALI Mice and macrophages.

2. Materials and Methods
2.1 Animals

Male C57BL/6 mice of this study, aged 6–8 weeks, weigh 18–22 g, were obtained from Chongqing Medical University. The entire study involved 15 mice. Each mouse was completely randomized into groups using a random number table. Before the experiment, the mice were kept free to eat and drink in specific pathogen free facility for at least 7 days. The Institutional Animal Care and Use Committee of Chongqing Medical University approved the procedures for the care and use of the mice. The First Affiliated Hospital of Chongqing Medical University Animal Ethics Committee approved the experimental scheme (reference number 2020-850).

2.2 CLP

Before performing CLP surgery, we administered inhalation anesthesia to the mice. In short, 5% isoflurane is used to induce anesthesia, and 2% isoflurane is used to maintain anesthesia. The operation method of CLP refers to previous research [21]. The cecum was exposed. Following a 5.0 mm ligation from the tip, puncture the cecal stump with a 22-gauge needle and squeeze out a small amount of intestinal contents. Sham operation control mice exposed cecal stump without ligation and puncture. After 24 h, all mice were euthanized via excessive carbon dioxide inhalation, and whole-blood and lung were collected for further analysis. Following ligation, 200 µL of PBS was administered into the right lung through the trachea and subsequently removed after 10 seconds as bronchoalveolar lavage fluid (BALF). Repeat the operation twice for the next analysis.

2.3 Dex Treatment

Mice were divided randomly by random number table into three groups (n = 5): (1) control; (2) CLP; and (3) CLP+Dex. Dexmedetomidine (SML0956, Sigma-aldrich, Darmstadt, Germany) was administered intraperitoneally at 50 µg/kg, 30 minutes post-CLP. The control mice intraperitoneally injected with the same amount of PBS. The dose of Dex was determined in previous studies [22, 23].

2.4 Histopathology

Lung tissue was fixed in paraformaldehyde (4%) for 24 hours (4 °C) and then embedded in paraffin. Then the slices were fixed on glass slides and stained with H&E (G1120, Solarbio, Beijing, China) to evaluate tissue damage with a photon microscope (Leica, Wetzlar, Germany). The lung-injury score results were obtained according to previously study of Mikawa et al. [24]. Alveolar congestion, hemorrhage, neutrophil infiltration, and transparent membrane formation were measured. Pathological damage was assessed using a 4-point scale: 0 = no or very slight damage, 1 = mild, 2 = moderate, 3 = serious, and 4 = very serious.

2.5 TUNEL Assay

Apoptosis was evaluated by TUNEL assay, following the methodology of a previous study [25]. Following the in situ cell apoptosis detection kit instructions (G001-1, Jiancheng Biotechnology, Nanjing, China), the lung sample was sealed, fixed, and sliced into 4-µm-thick sections. Proteinase K was used to digest the tissue for 15 minutes at 37 °C after the endogenous peroxidase was blocked. The terminal deoxynucleotidyl transferase was diluted in a reaction buffer and applied to sections at 37 °C for 2 hours, followed by three 2-minute washes. Slice with a dilution of anti-digoxin antibody incubation at 37 °C for 30 minutes. Apoptotic cells were measured by 3,3-diaminobenzidine chromogenic after about 20 min. For statistical analysis, three images were captured, and TUNEL-labeled cells were measured as reported previously [26].

2.6 Cytokine Measurement

An earlier study reported on the collection of whole blood and the preparation of serum [27]. Serum and BALF were analyzed with ELISA kits for interleukin (IL)-6, IL-10, tumor necrosis factor-alpha (TNF-α) and IL-17A (KMC0061, BMS614, BMS607-3, BMS6001, EBioscience, San Diego, CA, USA).

2.7 Immunofluorescence Staining

Rehydration and dewaxing of lung paraffin slices were performed. Triethylenediamine tetraacetic acid (GC202001, Servicebio, Wuhan, China) was used to retrieve antigens. Then sections were incubated with 5% BSA. The sections were incubated with anti-rat caspase-11 (1:100, NB120-10454, NOVUS, Littleton, CO, USA) or anti-mouse receptor for advanced glycation end products (RAGE, 1:100, ab37647, Abcam, Cambridge, UK) for 12 hours at 4 °C. Slices were incubated in the dark (room temperature) using either a FITC-labeled green secondary antibody (1:200, GB22403, Servicebio, Wuhan, China) for RAGE or a Cy3-labeled red secondary antibody (1:200, Servicebio, GB21302) for caspase-11. DAPI was applied to detected the nuclei. The immunofluorescence methods for inducible nitric oxide synthase (iNOS) and CD206 in RAW264.7 cells followed previously published protocols, with the primary antibodies substituted by rabbit anti-mouse CD206 antibody (1:100, 24595, Cell Signaling Technology, Danvers, MA, USA) and rat anti-mouse iNOS monoclonal antibody (1:1000, 740025T, Thermo Fisher Scientific, Waltham, MA, USA). FITC-goat anti-rat IgG (1:100, SA00003-11, proteintech, Wuhan, China) was used for iNOS, and goat anti-rabbit IgG-Cy3 (1:100, SA00009-2, proteintech, Wuhan, China) was used for CD206. Finally, the images were collected by confocal microscope (VS200-BU-L, OLYMPUS, Tokyo, Japan).

2.8 Western Blot

Total and nuclear protein samples in lung tissue and RAW264.7 cells were prepared using diluted RIPA Lysis Buffer and a nuclear extraction kit (P0013B, Beyotime, Shanghai, China). The prepared samples were transferred to polyvinylidene fluoride (PVDF) membrane after separation on sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE, 10–12%). After being washed and blocked at room temperature for 2 hours, the membranes were incubated with primary antibodies at 4 °C overnight: (RAGE, 1:100, ab37647, Abcam, Cambridge, UK), NF-κB p-p65 (1:1000, ab76302, Abcam, Cambridge, UK), IL-1β (1:1000, ab234437, Abcam, Cambridge, UK), gasdermin-D (1:1000, ab209845, Abcam, Cambridge, UK), iNOS (1:1000, ab202417, Abcam, Cambridge, UK), Arg-1 (1:5000, ab233548, Abcam, Cambridge, UK), caspase-11 (1:1000, NB120-10454, NOVUS, Littleton, CO, USA), GAPDH (1:50,000, A19056, ABclonal, Wuhan, China), β-actin (1:80,000, AC026, ABclonal, Wuhan, China), and histone H3 (1:1000, AF0863, Affinity, Jiangsu, China). The membrane was incubated with the secondary antibody, Goat Anti-Rabbit IgG (H+L) HRP (1:3000, S0001, Affinity, Jiangsu, China) or Goat anti-rat IgG (H+L) HRP (1:3000, S0009, Affinity, Jiangsu, China) at 37 °C for 1 hour after cleaning. Finally, the membrane was measured by ECL method (Immobilon® ECL UltraPlus Western HRP Substrate, #WBULP, Millipore, Billerica, MA, USA) using gel imaging systems software (Fusion, Vilber, Paris, French) was used to detect blot strength.

2.9 Quantitative Real-Time PCR (qRT-PCR) Assay

qRT-PCR experiments based on the description of the previous research [28]. In short, total mRNA samples were prepared from the lung tissue and RAW264.7 cells according to the RNAiso Plus reagent instructions. cDNA was synthesized using a Takara Technology cDNA synthesis kit. qRT-PCR was conducted using the TB Green™–Premix Ex Taq™ II reagent kit (RR820A, Takara, Kyoto, Japan) on a Bio-Rad CFX96 system (CFX96, Bio-Rad, Hercules, CA, USA) to evaluate the mRNA expression levels of RAGE, caspase-11, iNOS, Arg-1, IL-1β, and IL-6. The primer sequences are listed as follows (Tsingke-biology). Rage: sense 5-CTTGCTCTATGGGGAGCTGTA-3, antisense 5-CATCGACAATTCCAGTGGCTG-3; caspase-11: sense 5-CCTGAAGAGTTCACAAGGCTT-3, antisense 5-CCTTTCGTGTAGGGCCATTG-3; Inos: sense 5-CAGCTGGGCTGTACAAACCTT-3, antisense 5-CATTGGAAGTGAAGCGGTTCG-3; Arg-1: sense 5-GAACACGGCAGTGGCTTTAAC-3, antisense 5-TGCTTAGCTCTGTCTGCTTTGC-3; Il-1β: sense 5-GCAACTGTTCCTGAACTCAACT-3, antisense 5-ATCTTTTGGGGTCCGTCAACT-3; Il-6: sense 5-CAACGATGATGCACTTGCAGA-3, antisense 5-GTGACTCCAGCTTATCTCTTGGT-3; β-actin: sense 5-CCACCATGTACCCAGGCATT-3, antisense 5-CAGCTCAGTAACAGTCCGCC-3. The 2-Δ⁢Δ⁢Ct method was applied to detected the mRNA expression levels.

2.10 Peripheral Blood Mononuclear Cells (PBMCs) Isolation

Under anesthesia, whole blood samples were collected 24 hours post-CLP procedure, and PBMCs were isolated using Ficoll Histopaque (17544602, Cytiva, Logan, UT, USA) through density gradient centrifugation.

2.11 Cell Culture and Treatment

RAW 264.7 macrophage cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences, Shanghai, China. All cells were validated by STR profiling and tested negative for mycoplasma. After counting 105 cells, all were cultured in 90% high glucose DMEM with 10% heat-activated FBS (Gibco, Carlsbad, CA, USA) in a humidified environment at 5% CO2 and 37 °C. We began with 105 cells per group and cultured them until reaching 80% confluence in a six-well plate. Three groups were established: a control group, an lipopolysaccharide (LPS)-stimulated group (500 ng/mL), and an LPS+Dex group (10 µM). The dosage of LPS and Dex were determined in previous research [29, 30]. The cells were collected for analysis after 24 hours.

2.12 Flow Cytometry

Blank controls of harvested PBMCs and RAW264.7 cells underwent the same procedure as the samples, excluding flow-cytometry antibody staining. We used the fluorescent antibody of anti-CD11b-PerCP/Cyanine5.5 (101228, BioLegend, San Diego, CA, USA) and anti-F4/80-FITC (BioLegend, 123108) to test the macrophages in PBMCs. Fluorescent antibody staining was performed on cultured RAW264.7 cells and isolated PBMCs to assess the proportions of macrophage phenotypes (M1 CD86+; M2 CD206+). CD86 and CD206 were stained with anti-CD86-PE (105008, BioLegend, San Diego, CA, USA) and anti-CD206-APC (BioLegend, 141708), respectively, following the manufacturer’s instructions. A minimum of 105 cells were collected and analyzed using flow cytometer (DxFLEX, Beckman Coulter, Brea, CA, USA) and FlowJo V10 (BD Biosciences, Franklin Lakes, NJ, USA).

2.13 Statistical Analysis

Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Software Inc., San Diego, CA, USA) and SPSS 21.0 (IBM-SPSS Statistics, Chicago, IL, USA). A p-value 0.05 was deemed statistically significant. Results are expressed as mean (SD). Normality was assessed using the Shapiro-Wilk test. The Brown-Forsythe test and Bartlett’s test were utilized to confirm the homogeneity of variance assumption. One-way ANOVA was used to compare groups before Dunnett’s multiple comparison test.

3. Results
3.1 Dex had a Protective Effect on CLP Mice

The role of Dex in the CLP mice model was assessed by measuring lung damage through histological examination after H&E staining. Compared with the control group, the lung injury score in CLP group was significantly higher (p < 0.0001, Fig. 1A), due to severe congestion, hemorrhage, and neutrophil infiltration (Fig. 1A). However, lung injury severity was reduced by treatment with Dex (Fig. 1A). To assess lung injury severity, we conducted a TUNEL assay to measure apoptosis in lung tissue. The proportion of TUNEL-positive cells in the lungs of the CLP group was also significantly higher than control group (p < 0.0001, Fig. 1B), but Dex treatment decreased the proportion of these cells (Fig. 1B). Inflammation is a distinctive feature of acute lung injury. Elevated levels of inflammatory cytokines are sensitive indicators of ALI [31]. We detected the expression levels of cytokines in BALF and serum. The CLP challenge increased IL-6, TNF-α, and IL-17A levels in both BALF and serum, while Dex treatment reduced these pro-inflammatory cytokines (Fig. 1C). The release of IL-10 in CLP+Dex group was significantly more than that in CLP group (p < 0.001, Fig. 1C).

Fig. 1.

Dex treats lung injury in CLP mice. (A) H&E staining scores and representative pictures (Scale bar = 100 µm, 50 µm). (B) The TUNEL-positive cells in the lung (Scale bar = 100 µm, 50 µm). Five random fields (200×) were evaluated for positive cells. (C) Expression of cytokines in BALF and serum. (D) Nuclear p-p65 protein levels in mouse lung tissues. Use at least three independent experiment to calculate the mean (SD). n = 5. ns, no significance, *p < 0.05, ***p < 0.005, ****p < 0.0001. CLP, cecal ligation puncture; BALF, bronchoalveolar lavage fluid; Dex, Dexmedetomidine; IL, interleukin; TNF, tumor necrosis factor.

NF-κB significantly regulates inflammation by modulating pro-inflammatory cytokine production [32]. To evaluate Dex’s effect on NF-κB, the nuclear protein of mouse lung tissue was extracted and detected. The results suggested that Dex treatment significantly reduced CLP- mediated NF-κB (p65) nuclear translocation (p < 0.01; Fig. 1D).

3.2 Dex Inhibits RAGE/Caspase-11 Expression in the Lung of CLP Mice

ALI involves pyroptosis, a form of programmed cell death. Recent study indicates that the lethality of the CLP mice is primarily dependent on caspase-11 activation, with the mechanism involving coordinated activities of the RAGE and caspase-11/Gasdermin-D (GSDMD) pathways [33]. To determine if Dex mitigates CLP-induced lung injury by affecting expression of RAGE and caspase-11-dependent pyroptosis, we assessed pyroptosis-related protein and mRNA levels in lung tissue. qRT-PCR analysis revealed significantly elevated mRNA levels of Rage and caspase-11 in the CLP group exhibited higher levels than control group, but this difference was reduced with Dex treatment (Fig. 2A). Western blot analysis revealed that Dex treatment reduced the protein levels of cleaved-caspase-11, cleaved-GSDMD, and IL-1β. (Fig. 2B,C). Immunofluorescence images revealed elevated levels of RAGE (green) and caspase-11 (red) in CLP than in controls (p < 0.0001, Fig. 2D), and Dex treatment reduced RAGE and caspase-11 expression (Fig. 2D).

Fig. 2.

Dex inhibits RAGE/caspase-11 expression in the lung of CLP mice. (A) The lung mRNA levels of RAGE and caspase-11. (B) The RAGE protein levels in lung detected by western blotting. (C) Western blot detected the level of pyroptosis-related proteins. (D) Immunofluorescence assays of RAGE and caspase-11 (Scale bar = 50 µm, 20 µm). Use at least three independent experiment to calculate the mean (SD). n = 5. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001. RAGE, receptor for advanced glycation end products; IL, interleukin.

3.3 Dex Regulated M1 and M2 Macrophage Phenotypes in CLP-Induced Mice

Given the importance of M1 and M2 polarization in ALI development, a study was conducted to determine if Dex’s anti-inflammatory effects influence this polarization. Flow cytometry’ results founded that Dex treatment reduced the proportion of M1 (F4/80+CD86+) (p < 0.01, Fig. 3A), and elevated the proportion of M2 (F4/80+CD206+) (p < 0.05, Fig. 3A), relative to the CLP group. The Western blot results founded that Dex reduced the expression of iNOS (p < 0.01, Fig. 3B), which is the M1 macrophage biomarker. More importantly, Dex increased the expression of Arg-1 (p < 0.05, Fig. 3B), which is the recognized marker of M2 macrophages. We then used qRT-PCR to test the expression levels of macrophage polarization biomarkers. The qRT-PCR experiments confirmed the western blot assay results, demonstrating that Dex decreased iNOS mRNA levels while increasing Arg-1 mRNA levels (Fig. 3C).

Fig. 3.

Dex inhibited M1-type and promoted M2-type polarization in CLP-induced mouse model. (A) PBMCs were isolation and stained with F4/80-FITC/CD86-PE (M1) and F4/80-FITC/CD206-APC (M2), flow cytometry was used to test macrophage subset expression levels. (B,C) The western blot and qRT-PCR was used to test iNOS (M1) and Arg-1 (M2) expressed in the lung upon CLP-induced mouse model. Use at least three independent experiment to calculate the mean (SD). n = 5. ns, no significance, *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001. PBMCs, peripheral blood mononuclear cells; iNOS, inducible nitric oxide synthase; qRT-PCR, quantitative real-time PCR; M1, classical activation phenotype; M2, alternate activation phenotype; Arg-1, Arginase 1.

3.4 Dex Suppressed M1 and Promoted M2 Polarization in RAW264.7 Cells

In RAW264.7, qRT-PCR results demonstrated that the LPS+Dex group exhibited significantly lower Inos mRNA levels compared to the LPS group (p < 0.0001, Fig. 4A), and increased mRNA levels of Arg-1 (Fig. 4A). Western blot analysis revealed that the LPS+Dex group exhibited reduced iNOS protein expression and increased Arg-1 protein expression compared to the LPS group (Fig. 4B). Flow cytometry results showed that the LPS+Dex group had fewer M1 (CD86+) and more M2 (CD206+) compared to the LPS group (Fig. 4C). The images of immunofluorescence of RAW264.7 indicated that LPS challenge induced the high intensity of iNOS and suppressed the intensity of CD206 (Fig. 4D). Dex intervention reduced iNOS fluorescence intensity and enhanced CD206 fluorescence intensity in RAW264.7 (Fig. 4D).

Fig. 4.

Dex inhibited M1-and promoted M2-type polarization in LPS-Induced RAW264.7. (A,B) The qRT-PCR and western blot was used to test iNOS (M1) and Arg-1(M2) expressed in RAW264.7. (C) Flow cytometry was used to test macrophage subset expression levels of CD86-PE and CD206-APC in RAW264.7. (D) Immunofluorescence intensity of iNOS (green) and CD206 (red) in RAW264.7 (Scale bar = 20 µm). Use at least three independent experiment to calculate the mean (SD). n = 5. ns, no significance, *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001. iNOS, inducible nitric oxide synthase. LPS, ipopolysaccharide.

3.5 Dex Suppressed RAGE Expression and Caspase-11-Mediated Pyroptosis in RAW264.7

Macrophages play a major role in tissue homeostasis [34]. A recent study has indicated that caspase-11-induced macrophage pyroptosis is critical for the development of sepsis [35]. Over-activation of pyroptosis would lead to uncontrolled inflammation, and may aggravate the severity of ALI. In our in vitro experiments, immunofluorescence images showed that RAGE and caspase-11 intensities in the LPS group were higher than in controls, but were decreased in the LPS+Dex group (p < 0.0001, Fig. 5B). Western blot analysis demonstrated that Dex decreased LPS-induced expression of cleaved-caspase-11, RAGE, cleaved-GSDMD, and IL-1β (Fig. 5C,D). qRT-PCR results founded that Dex inhibited the mRNA levels of IL-1β and IL-6 (Fig. 5A).

Fig. 5.

Dex suppressed RAGE expression and caspase-11-mediated pyroptosis in RAW264.7. (A) The IL-1β and IL-6 mRNA levels in RAW264.7. (B) Immunofluorescence intensity of RAGE (green) and caspase-11 (red) in RAW264.7 (Scale bar = 20 µm). (C) RAGE protein levels detected by western blot. (D) Western blot detected the level of pyroptosis-related proteins. Use at least three independent experiment to calculate the mean (SD). n = 5. *p < 0.05, **p < 0.01, ****p < 0.0001. IL, interleukin.

4. Discussion

ALI is characterized by air-blood barrier disruption, hypoxemia, pulmonary edema and respiratory dysfunction [36]. Though advances in treatments for ALI have been made in recent years, there is still a high mortality rate. Substantial evidence suggests that it is significant that explosive and persistent inflammation in the progression of ALI [37], therefore, a potentially new treatment strategy to alleviate the progression of ALI could be based on regulating immune-system-mediated inflammatory responses [38]. Dex is known as is a short-acting, highly selective agonist of the α-2 adrenoreceptor that is widely used for its sedative, anxiolytic, analgesic, and sympatholytic effects [39]. Dex treatment provides perioperative hemodynamic stability and protects organs such as the heart, brain, and kidneys. The underlying mechanism may be related to reduced cell apoptosis, probably via Bax/Bcl-2-related effects [40] and by restraining release of pro-inflammatory cytokine [41]. In addition, recent research has indicated that treatment with Dex significantly alleviates lung injury likely by suppressing matrix metalloproteinase (MMP)-9 and MMP-2 [42].

Dex treatment reduced lung injury severity. The CLP+Dex group also showed a decrease in apoptosis of alveolar epithelial cells. Pro-inflammatory cytokines in BALF and serum are vital clinical features and meaningful indicators of ALI. Our study found that the expression levels of inflammation cytokines in serum and BALF of the experimental mice were lower after Dex treatment. The mechanism could be associated with inhibiting NF-κB (p65) nuclear translocation, which is a significant factor influencing the upstream regulator of inflammation activity. The regulatory effect of Dex on the inflammatory microenvironment is an important influence on phenotypic polarization of macrophages.

In recent years, research on immune regulatory inflammatory response to ALI has focused the exploration for effective therapies for ALI. Study reported that MSC-sEV has a therapeutic function on certain lung diseases, such as ALI, bronchopulmonary dysplasia and pulmonary hypertension, by immunoregulation of pulmonary macrophages [43]. Macrophages play a key role in the innate immune response in body. After contact with the pathogen, macrophages are activated to release various cytokines and other mediators [44]. In addition, macrophages are an essential medium for connecting the innate and acquired immune system responses. In the initial phase of ALI, M1 labeled with CD86 are stimulated by LPS, and other bacterial products, and release a variety of chemokines and cytokines. These cytokines promote neutrophil infiltration and activation, promoting the development of ALI [45]. M2 showing CD206 release insulin growth factor, platelet-derived growth factor, and TGF-β, which are all important in ALIf [46]. In the present study, we verified that Dex could act as an immune modulator to regulate macrophage phenotype in vivo and in vitro. We first used flow cytometry to detected the frequency of each macrophage subtype in different groups. Dex treatment could induce macrophages to undergo an M1-to-M2 switch. Macrophages marker Arg-1 (M2) and iNOS (M1) are crucial in regulating inflammatory functions. Arg-1 was the anti-regulatory enzyme of iNOS, which can inhibit iNOS activity and achieve the anti-inflammatory effect. In M2 macrophages, upregulated Arg-1 and downregulated iNOS contribute to the suppression of NO production, thus cutting off the pro-inflammatory signaling transduction and performing anti-inflammatory function [47]. We found lower protein and mRNA levels of iNOS in the CLP+Dex group than in the CLP group. The Arg-1 expression was much higher in the CLP+Dex group. Results of in vitro studies of RAW264.7 were consistent with the in vivo results. In fact, the differentiation of macrophages based on inflammatory phenotype has dynamic changes of proinflammatory and anti-inflammatory in different inflammatory phases. A more potent inflammatory phenotype eventually emerges after pro-inflammatory and anti-inflammatory tug-of-war. In ALI, there is a seesawing of pro-inflammatory and anti-inflammatory responses, and pro-inflammatory phenotypes dominate. In the present study, the level of M2 showed differentiated performance after inflammatory stimulation (CLP, LPS), including decreasing [48], not decreasing, and even increasing [49]. These conditions arise due to the dynamic resistance of M2 to the pro-inflammatory effects of M1. Our experimental results suggest that M2 levels did not decrease in the model group, and even slightly increased. This may be a response of M2 to inflammatory stimuli. In general, according to the in vivo and in vitro research, Dex treatment could restrain M1 polarization and promote M2 polarization. These results indicated that Dex alleviated ALI/ARDS partially by promoting macrophages M1-to-M2 polarization in vivo and in vitro.

Research increasingly indicates a close relationship between ALI severity and pyroptosis occurrence [20, 50, 51]. Pyroptosis is induced by canonical or non-canonical caspase-related signaling pathways [52], not only resulting cell death but also activating excessive inflammatory responses. RAGE has been found to have a vital role in the pathogenesis of ALI/ARDS. A previous study showed that RAGE as a vehicle is directly associated with LPS-induced pyroptosis [53]. In addition, AGE/RAGE signaling is essential in influencing the production and expression of TNF-α, oxidative stress, and endothelial dysfunction, which might aggravate ALI [54]. Our results indicated that RAGE, cleaved-caspase-11, cleaved-GSDMD, and IL-1β protein-expression levels were clearly lower in the lungs of mice after treatment with Dex than in CLP. The immunofluorescence images showed that Dex treatment suppressed the levels of RAGE and caspase-11 in the lung of CLP mice. Combined with the above results, the findings indicated that Dex was able to relieve the lung damage from CLP-induced damage and suppress inflammation.

Pyroptosis occurs when caspase-11 in macrophages is activated, and be for against intracellular bacteria and endotoxins [55]. Although the inflammatory response is crucial for the host to defend itself against invading microbes [56], overactivation of macrophages may lead to an inflammatory cascade effect, which results in tissue injury and multiple organ dysfunction [35]. Different subtypes of macrophage have been shown to be involved with tissues pyroptosis. Experimental results have indicated that LPS could regulate the transformation of the phenotype from the M2 to the M1 type, and then promote the pyroptosis of adipose tissue [57]. Those results are consistent with our study: Dex treatment elevated the proportion of M2-type macrophages and reduced pyroptosis of the lung. From those results, we concluded that M2-type macrophage polarization is associated with lung pyroptosis alleviation. Many researches have suggested that LPS promotes cell pyroptosis of RAW264.7 [58]; the cell model, RAW264.7 macrophages treated by LPS, is known as a canonical cell line model for inflammation research. Pyroptosis can be induced by numerous stimuli, however, and the mechanism still remains unknown. A research has stated that the transport of LPS into the cytosol is assisted by RAGE, which mediate caspase-11-dependent pyroptosis [53]. To identify whether Dex treatment could restrict macrophage pyroptosis, we used an LPS-stimulated RAW264.7 cell line model [59]. Our results provide evidence that Dex can inhibit inflammation and reduce lung injury caused by CLP. It could be associated with regulating M1 and M2 macrophage polarization and suppressing RAGE/Caspase-11-depended pyroptosis.

In summary, macrophage subtype imbalance and caspase-11 activation-induced pyroptosis played an essential role in ALI. Dex treatment could induce macrophages to undergo an M1-to-M2 switch and alleviate caspase-11-dependent macrophage pyroptosis to improve ALI/ARDS, reduce the inflammatory statement, and protect lung tissue. These findings could offer a novel therapeutic approach for ALI.

5. Conclusions

Dexmedetomidine treatment reduces lung damage in CLP mice and restrains the expression of proinflammatory cytokines. Dexmedetomidine may achieve its effects by promoting M2 macrophage polarization and suppressing caspase-11-dependent pyroptosis. These findings suggest that dexmedetomidine could act as an immune modulator to regulate macrophage polarization and provide protection against ALI.

Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author Contributions

YZ and SL made contributions to the conception or design of the work. YZ, KL, LW, GK, and KX participated in the work of data acquisition, analysis, and interpretation. YZ, KL, and KX drafted the manuscript. SL reviewed and revised Sthe manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

This study was approved by the Animal Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (Ref. 2020-850).

Acknowledgment

Not applicable.

Funding

This work was Sponsored by Natural Science Foundation of Chongqing, China (CSTB2024NSCQ-MSX0956 to SH Lin) and Innovation Project for Doctoral Students at the First Affiliated Hospital of Chongqing Medical University (CYYY-BSYJSCXXM-202209 to YS Zhao).

Conflict of Interest

The authors declare no conflict of interest.

References

Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.